| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
INNO-220 (compound INNO-220) (0.0001-10 μM, 24-72 h) exhibited broad-spectrum antiproliferative activity against lymphoma cell lines expressing wild-type p53 [1]. INNO-220 (0.0001-10 μM, 24-72 h) inhibited IL-2 in a CRBN-dependent manner [1]. INNO-220 (2-1250 nM, 24 h) inhibited lymphoma cell growth by activating apoptosis pathways and inducing cell cycle arrest at the G0/G1 phase [1]. INNO-220 (50 nM, 8 h) regulated the p53/NF-κB signaling pathway in OCI-Ly3 and Z-138 cells [1]. INNO-220 (2-1250 nM, 6-24 h) activates p53 in OCI-Ly3, Z-138 and OCI-Ly19 cells by CK1α degradation[1].
|
|---|---|
| ln Vivo |
INNO-220 (compound INNO-220) (3-20 mg/kg, administered by gavage daily for 43 days) can induce tumor regression in DLBCL and MCL xenograft models and inhibit NF-κB activity without significantly affecting mouse body weight, providing a new direction for lymphoma-related research [1].
|
| Cell Assay |
Cell viability assay [1]
Cell Types: 18 B-cell lymphoma cell lines, multiple wild-type p53 cell lines, diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) patient cells Tested Concentrations: 0.0001 μM, 0.001 μM, 0.01 μM, 0.1 μM, 1 μM, 10 μM Incubation Duration: 24 hours, 72 hours Experimental Results: Significantly inhibited the viability of wild-type p53 lymphoma cell lines (OCI-Ly3 cells, OCI-Ly10 cells, TMD8 cells, OCI-Ly19 cells, Will-2 cells, Z-138 cells). Significantly reduced the viability of primary patient cells. Significantly inhibited IL-2 secretion, while having little effect on the cell viability of PBMC and THLE-2 cells. It has no inhibitory effect on IL-2 in CRBN knockout Jurkat cells. Apoptosis analysis [1] Cell Types: OCI-Ly3 cells Tested Concentrations: 2 nM, 10 nM, 50 nM, 250 nM, 1250 nM Incubation Duration: 24 hours Experimental Results: Apoptosis was induced in a dose-dependent manner. PARP lysis and Caspase 3/8/9 expression were increased. Cell cycle analysis [1] Cell Types: OCI-Ly3 cells Tested Concentrations: 2 nM, 10 nM, 50 nM, 250 nM, 1250 nM Incubation Duration: 24 hours Experimental Results: Significantly increased the proportion of cells in the G0/G1 phase and decreased the proportion of cells in the S/G2/M phase.
|
| Animal Protocol |
Animal/Disease Models:A diffuse large B-cell lymphoma (DLBCL) xenograft model was established in male nude mice (4 weeks) [1].
Doses: 3 mg/kg, 10 mg/kg, 20 mg/kg Route of Administration: Daily gavage (ig), with the same dosage as above, for 43 days. Experimental Results: The 20 mg/kg dose significantly inhibited tumor growth. It degraded CK1α, upregulated p53 expression, and reduced Ki67 levels in tumor tissue. |
| References |
| Molecular Formula |
C23H20N4O3
|
|---|---|
| Molecular Weight |
400.43
|
| CAS # |
3032576-92-1
|
| Appearance |
White to off-white solid
|
| SMILES |
CN1N=CC(C2=CC3=C(C(N(C3)C4CCC(NC4=O)=O)=O)C=C2)=C1C5=CC=CC=C5
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2.5 mg/mL (~6.24 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4973 mL | 12.4866 mL | 24.9732 mL | |
| 5 mM | 0.4995 mL | 2.4973 mL | 4.9946 mL | |
| 10 mM | 0.2497 mL | 1.2487 mL | 2.4973 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
